Recent

% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, AŞ Message Board

  • gmc2500 gmc2500 May 24, 1999 8:59 PM Flag

    Forget RFS2000 Bring On GEMM-CSF

    Let me qualify this by message by stating I am a
    physician completing my residency in the midwest and have
    an extensive research background

    It's pretty
    amazing that the market cap for SUPG is only in the
    neighborhood of $400 million considering the huge potential
    for Rubitecan. It's not enough that this is the
    really the ONLY drug that has ever been shown to be of
    any value in the treatment of pancreatic cancer,
    which KILLS 25,000 persons per year in the US alone!
    But that this drug is taken orally thus eliminating
    the 2-3 day stay hospital stay (at about $1500/day)
    typically required for intravenous infusions like Gemzar.
    Supergen has worldwide rights which is good, because most
    cases of Pancreatic cancer occur in Asia and NOT in the
    USA.

    But all this aside. Rubitecan is NOT even Supergen's
    best drug in development. Look carefully at their
    website. They are already in phase 2 trails on an ORAL
    drug useful for aplastic anemia, it's biologcal name
    is GEMM-CSF. This is the mother of all blood growth
    factors. This drug combines the actions of THREE of the
    hottest selling drugs Neupogen (which is G-CSF, by
    Amgen), Epogen/Procrit (erythropoetin, J&J), and Neumega
    (M-CSF). Neupogen causes the bone marrow to make
    neutrophils, infection fighting white blood cells and is
    heavily used in chemotherapy patients. Erythropoetin
    causes the body to make new red blood cells ("blood) and
    is used virtually on ALL patients receiving
    hemodialysis and those receiving chemotherapy as it helps
    prevent anemia. Neumega causes the body to make platelets
    (which help blood clot) and is used in chemotherapy
    patients and others with bleeding disorders. Neupogen and
    erythropoetin together account for WELL OVER $1 billion per
    year in sales for their respective companies. In
    addition both of these medications are available by
    INJECTION only meaning patient's need to come to their
    doctor's office 3 times a week or have home nurse visits.
    Not so with Supergen, their drug is taken by mouth.
    In addition, many cancer patients need BOTH the
    effects of erythopoetin and Neupogen however these drugs
    counteract eachother when they are co-administered.
    Fortunately this does not occur with Supergen's GEMM-CSF, or
    whatever Supergen calls it. Supergen has orphan drug
    designation (I believe) to use GEMM-CSF for the treatment of
    aplastic anemia and is currently in phase II trials. Once
    approved by the FDA this drug WILL not only be used to
    treat aplastic anemia but will be a mainstay for
    chemotherapy and dialysis patients.
    Cha-chinggggg!!!!!!

    The medical community at large, myself excluded,
    including most hematologist/oncologists have no idea what
    Rubitecan is or that there is even such a thing called
    GEMM-CSF in development. Their loss is your gain.



    PS:
    Oh and by the way while I am at it, here is a SUPG
    tidbit that VIRTUALLY NOBODY KNOWS. There was a recently
    published article (look in Medline: key words 9NC and HIV)
    showing how 9 nitrocamptothecin (that's RUBITECAN) was
    effective in preventing HIV replication and may be useful
    as adjunctive therapy.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • joeclam you rascal. if your post is accurate then
      this is the reason why the name of the drug was
      changed. is supg merely marketing this drug and being a
      good shepherd? it appears they bought the rights from
      sthelin et al.

    • Thank you so much for your nice words and for
      your sympathy. I will stay on the board, though my
      contribution will be symbolic. I am not a physician, I am not
      a writer, I am not an investment advisor, I am just
      a business man with a lot of international
      management experience and a loving attitude for people in
      general and especially for those I care for. Have a good
      day to all.

    • My depest sympathy on the loss of Susan. My heart
      goes out to you. Thank you for sharing your
      experience. Please stay on the board, we're not always
      relevant, but we're here for you anytime.

      Best
      wishes, Anes.

    • <EOM>

    • progressively improved after 5FU and radiations
      in NY. While under Gemzar we could travel to Italy
      in October 1998, with no problems whatsoever.
      Quality of life further improved with Rubitecan: oral
      administration, less side effects including nausea and vomiting,
      improved tolerance to drug. We would travel to Orlando
      once a month for receiving pills for following 4
      weeks, have lab tests, and return. Other lab tests
      locally once a week. Susan was going to the pool every
      afternoon, reading and sun bathing. Because of the shingles
      ... everything came to an end; but the shingles
      restarted because of the blood values, so if it not for one
      thing ... it is for something else. In any case, when
      we are called, we better go!

      Sincerely hope
      that Rubitecan is soon approved to benefit the 29,000
      who every year get pancreatic cancer and die; plus,
      the many other forms of cancer, which amount to
      hundred of thousands.

      Appreciate the opportunity
      to comment on quality of life.

    • my mother's tumor markers were consistent with
      Susan's for the first three months after surgery and she
      was not even on FAM or RT. Markers rose very rapidly
      after 3rd month and died 5 months after diagnosis and
      surgery. So gemcitabine bought her a month and Rubitecan
      bought her more... and hopefully with quality of life.

    • My obviously unqualified medical opinion is as
      follows:

      Diagnosis & Surgery in March '98 followed by FAM and RT.
      Then patient went was treated with gemcitabine for
      approx. four months and tumor marker at 199 in mid-Sept.
      That is six months after diagnosis and pt. has
      survived approximately one month over normal max. This is
      not too unusual for gemcitabine from what I
      understand.

      Given time progression and progressive disease, it
      appears, to me anyway, that gemcitabine is no longer
      effective. Pt. is moved to RFS2000, two months later with
      Progressive Disease.

      From the perspective of someone
      who understands the RAPID progression of this disease
      and who has seen tumor markers rise WELL above these
      in much shorter periods of time, Rubitecan, although
      did not bring about "Stable Disease" in this patient
      (that's what I'm reading anyway) certainly appears to me
      to have slowed down the very rapid progression that
      would have occurred at this point in time. I have seen
      tumor markers rise 10,000 in 1 week! Rubitecan was now
      possibly "regulating" (non medical term) progression at
      this juncture and patient survived for what appears to
      be 15 months after diagnosis.

      What should
      also be taken into consideration is Quality of Life.
      Adso, was Susan feeling better on Rubitecan and able to
      do more? Did she tolerate the drug
      well?

      Also, take into consideration that this patient started
      Rubitecan after normal life expectancy after surgery and
      during a time period when rapid progression and death
      would have probably occurred within days to weeks, not
      months.

      But again, Quality of Life and survival are the
      key.

      Again, one case. Many people start sooner and survive
      longer according to Stehlin.

      I believe in this
      drug and would have like to have this in
      1996.

      Adso, can you comment on Quality of Life before
      shingles, which naturally would force her off of trial?

    • are the tumor markers values, resulting from
      specific blood analysis. An oncologist could explain it
      better, if this is not enough. Dr. Andrasda could explain
      it better.

      The end ... means ...
      death!

      Sorry.

    • Understanding that any single individual's
      experience is NOT projectable ...

      I don't understand
      the numbers you posted for patient Susan. Could you
      explain please?

      On 9/11 the tumor marker was 199.
      Under normal conditions it should be <33, I am told.
      Look at this:

      11/18/98 2150 still Gemzar, but
      decreasing effectiveness
      ----> What is the #
      2150???
      01/13/99 4,200 Gemzar stopped working
      01/26/99 7,937 no
      chemo, looking frenziedly for new drug
      02/03/99 start
      RFS 2000
      03/02/99 8150 RFS 2000
      03/31/99 13750
      RFS 2000
      04/27/99 16580 RFS 2000
      05/02/99
      admittance to hospital due to shingles attack and

      dehydration - no RFS 2000 because of low blood
      values
      05/25/99 43910 no RFS 2000 - still at hospital
      06/15/99
      the end -----> is this the end of your info or the
      end of poor Susan?

    • for Susan. She was operated of pancreatic cancer
      on March 2, 1998 at Mount Sinai in NY. Chemo (5FU) +
      Radiations. Killing therapy. Back to Florida in May. Started
      Gemzar in June. It worked fine till autumn. On 9/11 the
      tumor marker was 199. Under normal conditions it should
      be <33, I am told. Look at this:
      11/18/98 2150
      still Gemzar, but decreasing effectiveness
      01/13/99
      4,200 Gemzar stopped working
      01/26/99 7,937 no
      chemo, looking frenziedly for new drug
      02/03/99 start
      RFS 2000
      03/02/99 8150 RFS 2000
      03/31/99 13750
      RFS 2000
      04/27/99 16580 RFS 2000
      05/02/99
      admittance to hospital due to shingles attack and

      dehydration - no RFS 2000 because of low blood
      values
      05/25/99 43910 no RFS 2000 - still at hospital
      06/15/99
      the end.

      The trend shows to me that RFS 2000
      (now Rubitecan) has worked at keeping the tumor marker
      progression under control.

      It is just one case, but it
      worked. Thanks Rubitecan.

      Draw your own
      conclusions!

      It would be beneficial to hear more of this cases
      and maybe limit out-of-contest postings.

      Best
      wishes to all investors in SUPG and especially to those
      patients who are taking Rubitecan.

    • View More Messages